Phaseline

Targets › DHFR

DHFR (Dihydrofolate reductase): drug programs, companies and trials

34 programs from 28 companies in 47 trials: 22 Phase 2, 11 Phase 3, 11 Phase 1, 3 Phase 4; Oncology, Infectious disease, Immunology; next expected readout Dec 2026.

Catalyzes the reduction of 7,8-dihydrofolate (DHF) to 5,6,7,8-tetrahydrofolate in a NADPH-dependent manner. Key enzyme in folate metabolism. (UniProt, P00374)

Open in Phaseline: the race on DHFR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tongji HospitalTrimethoprim
Bacterial dihydrofolate reductase inhibitor
DHFR, DHPSPhase 4Pneumonia, PneumocystisDec 2026
Indiana UniversityTrimethoprim-sulfamethoxazole (TMP-SMX)
Dihydropteroate synthase and dihydrofolate reductase inhibitor; inhibits bacterial folate
DHPS, DHFRPhase 4Methicillin Resistant Staphylococcus AureusJun 2027
National Institute of Allergy and Infectious Diseases (NIAID)Pyrimethamine
Dihydrofolate reductase inhibitor
DHFRPhase 4ToxoplasmosisDec 2030
Kyungpook National University HospitalFOLFOX-6
Combination chemotherapy: oxaliplatin (platinum agent), leucovorin (reduced folate), and 5
DPYD, TYMS, DHFRPhase 3Colon CancerDec 2026
Acrotech BiopharmaPralatrexate
Dihydrofolate reductase inhibitor
DHFRPhase 3Peripheral T Cell Lymphoma; Advanced Solid Tumors; Lymphoma, T-Cell; PTCL …Feb 2027
Centre Hospitalier Universitaire Dijonmodified FOLFOX
Multi-drug chemotherapy: folate antagonist (folinic acid), thymidylate synthase inhibitor
TOPO2, TYMS, DHFR, SLC22A16Phase 3Colon Cancer; Locally Advanced or Metastatic Small Bowel AdenocarcinomaFeb 2027
Seoul National University HospitalmFOLFIRINOX (preoperative)
Multi-agent chemotherapy combining irinotecan (topoisomerase I inhibitor), fluorouracil (t
TOPO1, DHFR, TYMSPhase 3Resectable Pancreatic CancerDec 2027
Tampere UniversitySulfadoxine
Dihydropteroate synthetase inhibitor
DHPS, DHFRPhase 3MalariaDec 2027
Fudan UniversityXELOX adjuvant chemotherapy
Multi-agent chemotherapy: oxaliplatin (platinum agent) and capecitabine (5-fluorouracil pr
DHFR, TYMS, SLC22A16Phase 3High-risk Stage II Colorectal CancerJun 2028
Fudan UniversitymFOLFIRINOX adjuvant chemotherapy
Multi-agent chemotherapy: oxaliplatin (platinum agent), irinotecan (topoisomerase I inhibi
DHFR, TYMS, TOPO1, SLC22A16Phase 3High-risk Stage II Colorectal CancerJun 2028
Fudan UniversitymFOLFOX6 adjuvant chemotherapy
Multi-agent chemotherapy: oxaliplatin (platinum agent), leucovorin (folinic acid), and 5-f
DHFR, TYMS, SLC22A16Phase 3High-risk Stage II Colorectal CancerJun 2028
Kyungpook National University HospitalFOLFOX
Combination chemotherapy: 5-fluorouracil + leucovorin + oxaliplatin
DHFR, TYMSPhase 3Colon CancerDec 2028
Sixth Affiliated Hospital, Sun Yat-sen UniversityCapeOx chemotherapy regimen
Capecitabine/oxaliplatin combination chemotherapy
TYMS, DHFRPhase 3Colorectal CancerFeb 2031
Sixth Affiliated Hospital, Sun Yat-sen UniversityFOLFOX chemotherapy regimen
5-FU/leucovorin/oxaliplatin combination chemotherapy
TYMS, DHFRPhase 3Colorectal CancerFeb 2031
Ruijin HospitalS-1
Oral fluoropyrimidine (tegafur/5-FU/gimeracil/oteracil combination)
TYMS, DHFRPhase 2Pancreatic Neoplasms; Gastric or Esophagogastric Junction AdenocarcinomaDec 2026
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Trimethoprim
Bacterial dihydrofolate reductase inhibitor
DHFRPhase 2EczemaJan 2027
Rutgers, The State University of New JerseysFOLFOXIRI (alternating FOLFOX and FOLFIRI)
Fluorouracil-based chemotherapy combining FOLFOX (5-fluorouracil, leucovorin, oxaliplatin)
DHFR, TYMS, TOPO1Phase 2Gastro-Intestinal CancerFeb 2027
Lithuanian University of Health SciencesFOLFOX4
Combination chemotherapy with oxaliplatin (platinum agent), 5-fluorouracil (thymidylate sy
DHFR, TYMSPhase 2Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOXJun 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyS-1
Fluoropyrimidine combination (5-FU prodrug with CDHP and OXO)
TYMS, DHFRPhase 2Gastric CancerJul 2027
Tianjin Medical University Cancer Institute and HospitalLeucovorin (LV)
Reduced folate cofactor enhancing 5-FU activity
DHFRPhase 2Colorectal Cancer (CRC)Aug 2027
Qingdao Central HospitalTAS-102
5-FU prodrug with thymidylate synthase and dihydrofolate reductase inhibition
TYMS, DHFRPhase 2EFSDec 2027
Mayo ClinicPemetrexed Disodium
Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor
TYMS, DHFR, GARTPhase 2Metastatic Salivary Gland CarcinomaFeb 2028
Fudan UniversitymFOLFIRINOX plus IMRT
Multi-drug chemotherapy regimen (5-fluorouracil, folinic acid, irinotecan, oxaliplatin) co
TOPO1, DPYD, TYMS, DHFRPhase 2Pancreatic Adenocarcinoma; Pancreatic CancerMar 2028
Dartmouth-Hitchcock Medical Centermodified FOLFIRINOX (mFOLFIRINOX)
Combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin; multi-targeted che
TYMS, DHFRPhase 2Pancreas AdenocarcinomaJul 2028
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityTegafur
Antimetabolite (prodrug of fluorouracil)
TYMS, DHFRPhase 2ImmunotherapySep 2028
UNICANCERLonsurf (Trifluridine/tipiracil)
Thymidylate synthase inhibitor and DHFR inhibitor combination; trifluridine is a nucleosid
TYMS, DHFRPhase 2Metastatic Colorectal CancerOct 2028
NRG OncologyPemetrexed Disodium
Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor
TYMS, DHFR, GARTPhase 2Recurrent Non-Small Cell Lung CarcinomaDec 2028
Centre Georges Francois LeclercFOLFIRINOX3
Combination chemotherapy: 5-FU (thymidylate synthase inhibitor), irinotecan (topoisomerase
TYMS, DHFRPhase 2Metastatic Pancreatic CancerJul 2029
Duke UniversityFLOT
5-FU + Leucovorin + Oxaliplatin + Docetaxel (antimetabolite + folinic acid + platinum alky
TYMS, DHFRPhase 2Esophageal AdenocarcinomaSep 2029
Duke UniversityModified-FOLFOX-6
5-FU + Leucovorin + Oxaliplatin (5-FU thymidylate synthase inhibitor + folinic acid + plat
TYMS, DHFRPhase 2Esophageal AdenocarcinomaSep 2029
Ashish ShahDB107-FC
Flucytosine; prodrug converted by cytosine deaminase to fluorouracil
TYMS, DHFRPhase 2High Grade GliomaMay 2034
Clinica Universidad de Navarra, Universidad de NavarraTTFields
Combination chemotherapy: folate antagonist (5-FU/leucovorin), topoisomerase I inhibitor (
TYMS, DHFRPhase 1Pancreatic Adenocarcinoma MetastaticMar 2027
National Cancer Institute (NCI)Pemetrexed Disodium
Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; GAR transformylase inhibitor
TYMS, DHFR, GARTPhase 1Epithelioid Mesothelioma; Biphasic MesotheliomaMar 2027
University of Texas Southwestern Medical CenterLeucovorin
Folinic acid; enhances 5-fluorouracil activity
DHFRPhase 1Gastro-esophageal Junction (GEJ) CancerOct 2027

Conditions

Colon Cancer (3) High-risk Stage II Colorectal Cancer (3) Colorectal Cancer (2) Gastric Cancer (2) Esophageal Adenocarcinoma (2) Pancreatic Adenocarcinoma Metastatic (2) EFS (2) Malaria (1) Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX (1) Pancreas Adenocarcinoma (1) Locally Advanced or Metastatic Small Bowel Adenocarcinoma (1) Colorectal Cancer (CRC) (1)

Modalities

small molecule (24), mixed (4), antibody (1)

Companies

Fudan University (4) Sixth Affiliated Hospital, Sun Yat-sen University (2) Duke University (2) Kyungpook National University Hospital (2) Tampere University (1) Lithuanian University of Health Sciences (1) Dartmouth-Hitchcock Medical Center (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Centre Hospitalier Universitaire Dijon (1) Tianjin Medical University Cancer Institute and Hospital (1) Ashish Shah (1) NRG Oncology (1) UNICANCER (1) Rutgers, The State University of New Jersey (1) Centre Georges Francois Leclerc (1) Tongji Hospital (1) Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) University of Texas Southwestern Medical Center (1) Acrotech Biopharma (1) National Cancer Institute (NCI) (1)

Related targets

TYMS (26) SLC22A16 (4) TOPO1 (4) DHPS (3) GART (3) DPYD (2) TOPO2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.